Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Impact of a single 10 min education session on asthma control as measured by ACT.

Schuermans D, Hanon S, Wauters I, Verbanck S, Vandevoorde J, Vanderhelst E.

Respir Med. 2018 Oct;143:14-17. doi: 10.1016/j.rmed.2018.08.003. Epub 2018 Aug 12.

PMID:
30261986
2.

Quality of care and variability in lung cancer management across Belgian hospitals: a population-based study using routinely available data.

Vrijens F, De Gendt C, Verleye L, Robays J, Schillemans V, Camberlin C, Stordeur S, Dubois C, Van Eycken E, Wauters I, Van Meerbeeck JP.

Int J Qual Health Care. 2018 May 1;30(4):306-312. doi: 10.1093/intqhc/mzy027.

PMID:
29506181
3.

Patterns of care for non-small cell lung cancer patients in Belgium: A population-based study.

Verleye L, De Gendt C, Vrijens F, Schillemans V, Camberlin C, Silversmit G, Stordeur S, Van Eycken E, Dubois C, Robays J, Wauters I, Van Meerbeeck JP.

Eur J Cancer Care (Engl). 2018 Jan;27(1). doi: 10.1111/ecc.12747. Epub 2017 Aug 18.

PMID:
28833865
4.

The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database.

Vrancken A, Lepers S, Peeters L, Oyen C, Dooms C, Nackaerts K, Verbeken E, Wauters I, Weynand B, Vansteenkiste J.

Lung Cancer. 2016 Dec;102:96-100. doi: 10.1016/j.lungcan.2016.11.003. Epub 2016 Nov 6.

PMID:
27987596
5.

Beyond the Diketopiperazine Family with Alternatively Bridged Brevianamide F Analogues.

Wauters I, Goossens H, Delbeke E, Muylaert K, Roman BI, Van Hecke K, Van Speybroeck V, Stevens CV.

J Org Chem. 2015 Aug 21;80(16):8046-54. doi: 10.1021/acs.joc.5b01161. Epub 2015 Aug 3.

PMID:
26193166
6.

The association between lesion location and functional outcome after ischemic stroke.

Yassi N, Churilov L, Campbell BC, Sharma G, Bammer R, Desmond PM, Parsons MW, Albers GW, Donnan GA, Davis SM; EPITHET Investigators; DEFUSE Investigators.

Int J Stroke. 2015 Dec;10(8):1270-6. doi: 10.1111/ijs.12537. Epub 2015 Jun 4.

PMID:
26045301
7.

Immunotherapy for non-small-cell lung cancer: the past 10 years.

Vansteenkiste J, Craps J, De Brucker N, Wauters I.

Future Oncol. 2015 Oct;11(19):2681-2695. doi: 10.2217/fon.15.116. Epub 2015 May 20.

PMID:
26039564
8.

Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study.

Hantson I, Dooms C, Verbeken E, Vandenberghe P, Vliegen L, Roskams T, Vander Borght S, Nackaerts K, Wauters I, Vansteenkiste J.

Transl Respir Med. 2014 Dec;2(1):9. doi: 10.1186/s40247-014-0009-0. Epub 2014 Sep 11.

9.

Preparation of phosphines through C-P bond formation.

Wauters I, Debrouwer W, Stevens CV.

Beilstein J Org Chem. 2014 May 9;10:1064-96. doi: 10.3762/bjoc.10.106. eCollection 2014. Review.

10.

Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer.

Adam V, Wauters I, Vansteenkiste J.

Expert Opin Biol Ther. 2014 Mar;14(3):365-76. doi: 10.1517/14712598.2014.880421. Epub 2014 Jan 24. Review.

PMID:
24456101
11.

Chemotherapy-induced anemia: the story of darbepoetin alfa.

Vansteenkiste J, Wauters I, Elliott S, Glaspy J, Hedenus M.

Curr Med Res Opin. 2013 Apr;29(4):325-37. doi: 10.1185/03007995.2013.766593. Epub 2013 Feb 11. Review.

PMID:
23323876
12.

Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.

Wauters I, Vansteenkiste J.

Expert Rev Anticancer Ther. 2012 Nov;12(11):1383-90. doi: 10.1586/era.12.117. Epub 2012 Oct 31. Review.

PMID:
23113603
13.

Clinical factors predictive of long-term survival in advanced non-small cell lung cancer.

Van Damme V, Govaerts E, Nackaerts K, Dooms C, Wauters I, Vansteenkiste J.

Lung Cancer. 2013 Jan;79(1):73-6. doi: 10.1016/j.lungcan.2012.09.015. Epub 2012 Oct 18.

PMID:
23083516
14.

Maintenance therapy for advanced non-small-cell lung cancer: a pilot study on patients' perceptions.

Peeters L, Sibille A, Anrys B, Oyen C, Dooms C, Nackaerts K, Wauters I, Vansteenkiste J.

J Thorac Oncol. 2012 Aug;7(8):1291-5. doi: 10.1097/JTO.0b013e31825879ea.

15.

Maintenance therapy for advanced non-small-cell lung cancer: ready for clinical practice?

Sibille A, Wauters I, Vansteenkiste J.

Expert Rev Anticancer Ther. 2012 Apr;12(4):529-39. doi: 10.1586/era.12.22. Review.

PMID:
22500689
16.

Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development.

Decoster L, Wauters I, Vansteenkiste JF.

Ann Oncol. 2012 Jun;23(6):1387-93. doi: 10.1093/annonc/mdr564. Epub 2011 Dec 12. Review.

PMID:
22156658
17.

Erythropoiesis-stimulating agents in cancer patients: reflections on safety.

Wauters I, Vansteenkiste J.

Expert Rev Clin Pharmacol. 2011 Jul;4(4):467-76. doi: 10.1586/ecp.11.22. Review.

PMID:
22114856
18.

Greater effect of stroke thrombolysis in the presence of arterial obstruction.

De Silva DA, Churilov L, Olivot JM, Christensen S, Lansberg MG, Mlynash M, Campbell BC, Desmond P, Straka M, Bammer R, Albers GW, Davis SM, Donnan GA; EPITHET-DEFUSE Investigators.

Ann Neurol. 2011 Oct;70(4):601-5. doi: 10.1002/ana.22444.

19.

Impact of FDG-PET-induced treatment choices on long-term outcome in non-small cell lung cancer.

Wauters I, Stroobants S, De Leyn P, D'Hoore I, Nackaerts K, Dooms C, Vansteenkiste J.

Respiration. 2010;79(2):97-104. doi: 10.1159/000218167. Epub 2009 May 7.

20.

Darbepoetin alfa in the treatment of chemotherapy-induced anaemia.

Wauters I, Vansteenkiste J.

Expert Opin Biol Ther. 2009 Feb;9(2):221-30. doi: 10.1517/14712590802652280 . Review.

PMID:
19236252

Supplemental Content

Loading ...
Support Center